Artículos de revistas
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis
Fecha
2020-11-01Registro en:
Revmatologiia (Bulgaria), v. 59, n. 11, p. 3505-3514, 2020.
1310-0505
10.1093/rheumatology/keaa240
2-s2.0-85094932332
7098310008371632
0000-0002-7631-7093
Autor
IRCCS Istituto Giannina Gaslini
Università degli Studi di Genova
Ain Shams University
Institute of Child Health
SRCC Children's Hospital
Mahidol University
R G Kar Medical College
IRCCS Ospedale Pediatrico Bambino Gesù
Sir Ganga Ram Hospital
Benha University
Alexandria University
Tanta University
Cairo University
Universidade do Estado do Rio de Janeiro (UERJ)
Universidade Federal do Rio de Janeiro (UFRJ)
Hospital de Pediatría Garrahan
University of Milan
University Hospital Meyer
National Medical Research Center of Children's Health
Sechenov First Moscow State Medical University
Queen Rania Children's Hospital
Saint-Petersburg State Pediatric Medical University
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Suez Canal University
King Faisal Specialist Hospital and Research Center
Università degli Studi di Palermo
Universidade Estadual Paulista (Unesp)
Azienda Ospedaliera Universitaria Gaetano Martino Messina
Azienda Ospedaliera Universitaria Gaetano Martino
Kanazawa University
Ospedale Vito Fazzi
AON SS Antonio e Biagio e Cesare Arrigo Children's Hospital
Institución
Resumen
Objective. To develop a composite disease activity score for systemic JIA (sJIA) and to provide preliminary evidence of its validity. Methods. The systemic Juvenile Arthritis Disease Activity Score (sJADAS) was constructed by adding to the four items of the original JADAS a fifth item that aimed to quantify the activity of systemic features. Validation analyses were conducted on patients with definite or probable/possible sJIA enrolled at first visit or at the time of a flare, who had active systemic manifestations, which should include fever. Patients were reassessed 2 weeks to 3 months after baseline. Three versions were examined, including ESR, CRP or no acute-phase reactant. Results. A total of 163 patients were included at 30 centres in 10 countries. The sJADAS was found to be feasible and to possess face and content validity, good construct validity, satisfactory internal consistency (Cronbach's alpha 0.64-0.65), fair ability to discriminate between patients with different disease activity states and between those whose parents were satisfied or not satisfied with illness outcome (P < 0.0001 for both), and strong responsiveness to change over time (standardized response mean 2.04-2.58). Overall, these properties were found to be better than those of the original JADAS and of DAS for RA and of Puchot score for adult-onset Still's disease. Conclusion. The sJADAS showed good measurement properties and is therefore a valid instrument for the assessment of disease activity in children with sJIA. The performance of the new tool should be further examined in other patient cohorts that are evaluated prospectively.